Webinar: Future of COVID-19 Research

**Update October 28th, 2021 ** Thank you to everyone that attended our webinar! We had a great turnout-- in case you missed the presentations or you would like to watch them again, you can now stream them below or on our YouTube channel.

visual: background image courtesy of National Institute of Allergy and Infectious Diseases


Description: The BRCCH cordially invites you to join us online for a webinar looking at The Future of COVID-19 Research. This event will highlight significant research progress and the roadmap ahead related to immunology, epidemiology and bioengineering. Gain insights from our keynote speakers and engage with them during the Q&A panel discussion.

When: Thursday, October 21st, 2021 from 15:00-17:00 CET

Where: online, livestream Zoom seminar

Welcome by BRCCH Vice Director Prof Sai Reddy
Keynote lecture by Prof Teresa Lambe OBE (University of Oxford)
     "Development and testing of the Oxford/AstraZeneca vaccine"
Keynote lecture by Prof Benjamin Murrell (Karolinska Institutet)
     "Neutralizing SARS-CoV-2 variants"
Keynote lecture by Prof Sai Reddy (ETH Zurich and BRCCH)
     "Identifying prospective variants of SARS-CoV-2 by deep mutational learning"
Q&A Panel Discussion

Webinar Archive

Prof Teresa Lambe OBE (University of Oxford) presents "Development and Testing of the ChAdOx1 nCoV-19/AZD1222 Vaccine" originally webcast on October 21st, 2021.


Prof Benjamin Murrell (Karolinska Institutet) presents "Neutralizing SARS-CoV-2 Variants" originally webcast on October 21st, 2021.


Prof Sai Reddy (ETH Zurich and BRCCH) presents "Identifying Prospective Variants of SARS-CoV-2 by Deep Mutational Learning" originally webcast on October 21st, 2021.

Keynote Speakers:

Prof Teresa Lambe OBE
The Lambe Group for Emerging Pathogens
The Oxford Vaccine Group and the Jenner Institute Laboratories
Dept of Paediatrics, University of Oxford

Assoc Prof Lambe will share her research insights into the immune response to SARS-CoV-2 and its vaccine. Her research group is part of the Covid-19 vaccine trial in the UK and has co-designed the vaccine and led the development and testing of the immune response after vaccination.

Prof Lambe’s research investigates the establishment of protective immune responses following vaccination and the formation of adaptive immune memory. She is particularly interested in delineating the immune response post vaccination and also post natural infection to help develop vaccines and define correlates of protection. At the University of Oxford, her group uses platform technologies to develop vaccines against emerging and re-emerging pathogens. The group is currently developing vaccines against a number of outbreak pathogens including Crimean-Congo haemorrhagic fever virus, Lassa virus, Nipah virus, Influenza, Ebolavirus and coronaviruses.

Visual: John Cairns/University of Oxford

Prof Benjamin Murrell
Department of Microbiology, Tumor and Cell Biology
Karolinska Institutet

Prof Murrell will speak about his work on the H2020 CoroNAb project, studying antibodies and isolating nanobodies against SARS-CoV-2.

Prof Murrell's previous research interests surrounded the evolution of the HIV envelope protein, and antibodies against it. Recently, he has applied this expertise to SARS-CoV-2 and its variants. Together with colleagues, he has identified nanobodies from immunized alpacas that may be potential SARS-CoV-2 therapeutics, and has conducted preclinical immunization studies attempting to boost responses to SARS-CoV-2 variants. This work is part of the CoroNAb consortium research project, funded under Horizon2020 as part of the EU’s emergency funding call for COVID-19.

Visual: Karolinska Institutet

Prof Sai Reddy
Laboratory for Systems and Synthetic Immunology
Department of Biosystems Science and Engineering, ETH Zurich
And Vice Director BRCCH

Prof Reddy shares his recent work on developing a simultaneous diagnostic and genomic surveillance method for SARS-CoV-2 based on targeted deep sequencing. He will also present new data from his group related to identifying variants of SARS-CoV-2 using a novel method called deep mutational learning. 

Prof Reddy’s research is focused on the emerging field of systems and synthetic immunology, with an aim towards developing technologies relevant to immunotherapy and biotechnology. He has developed a number of methods in systems immunology to improve our understanding of adaptive immunity, with a particular focus on immune repertoire sequencing. Recently, he founded two spin-off companies, deepCDR Biologics and Engimmune Therapeutics, which are both based on technologies developed in his research group on engineering antibodies or T cells.